Open AccessP968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION‐FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202
Author(s) -
Voorhees P.,
Suman V.,
Efebera Y.,
Raje N.,
Tuchman S.,
Rodriguez C.,
Santo K.,
BovaSolem M.,
Carlisle D.,
Saad U.,
McCarthy P.,
Richardson P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846740.75414.50
Subject(s) - pomalidomide , lenalidomide , ixazomib , medicine , clinical endpoint , multiple myeloma , carfilzomib , maintenance therapy , dexamethasone , bortezomib , oncology , randomized controlled trial , surgery , gastroenterology , chemotherapy